TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p

SIMPLE SUMMARY: An estimated ~25–30% of patients with advanced prostate cancer (PCa) develop the aggressive and lethal form of the disease known as treatment-induced neuroendocrine prostate cancer (t-NEPC). Owing to lack of treatment options, the identification of the underlying molecular mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Girijesh Kumar, Dutta, Sayanika, Mahmud Syed, Mosharaf, Ramachandran, Sabarish, Sharma, Monica, Rajamanickam, Venkatesh, Ganapathy, Vadivel, DeGraff, David J., Pruitt, Kevin, Tripathi, Manisha, Nandana, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507954/
https://www.ncbi.nlm.nih.gov/pubmed/34638504
http://dx.doi.org/10.3390/cancers13195020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507954/
https://www.ncbi.nlm.nih.gov/pubmed/34638504
http://dx.doi.org/10.3390/cancers13195020

Ejemplares similares